What gives chill and scare to humans in theatres while watching movies on viral pandemics happened in real-time in mainland Wuhan China to reflect the reality that such outbreaks of mammoth proportions are not only possible but can cause loss of human life and a global economic recession to come (1). It appears that we haven’t learned from the past experiences with the emergence of a cross-species viral infections and dangers of its transmission with diseases like Ebola, MERS and SARS (2, 3), as investment by even first world countries into the research to prevent and tackle the emergence of outbreak of lethal viral epidemics has remained insignificant. The scientific and healthcare community on the other hand, at times like past SARS outbreak and recent COVID–19 epidemic, has always come forward to help with their expertise to combat such occurrences (4, 5, 6, 7) without any material ravenousness. Management of the outbreaks and attempts to contain the current COVID–19 crisis has proven to be monumental with the risk of it outbreaks that could go global (8) along with no vaccine and specific drugs that target the COVID–19 virus, the feeling of being helpless to combat the COVID–19 epidemic is frustrating and ominous. The fast and dedicated work of the scientists (9, 10) and devoted organization (11, 12, 13) have managed to archive the genome of COVID–19 and its different mutants in a very short time that gives an opportunity to explore and elucidate the molecular targets encoded by the COVID–19. Being taxonomically related to coronaviridae group of viral pathogens (9, 10), the COVID–19 shares a significant similarity with other members that are known to have caused similar if not identical cross-species viral diseases in humans (9, 14, 15). Examples of the latter include SARS (2002 to 2004) and MERS that affected the human population in 2012 (14, 15). The SARS genome (NCBI Reference Sequence: NC_004718.3) is known to encode 13 proteins, of which the surface glycoprotein (sGP) (NCBI Reference Sequence: NP_828851.1) is known to be essential to dock the virus to angiotensin-converting enzyme 2 (ACE2) receptor on host cells in the pulmonary parenchyma (9, 10, 14). It was inferred that like both, SARS-nCoV and COVID–19, belong to the same betacoronavirus (14, 15) they would have a similar if not identical composition of the sGP that help to dock on ACE2 receptors (16, 17). in human cells before gaining entry into the host cells. It is important to mention here that an antigenic similarity between both the sGP of COVID–19 and SARS-CoV can be exploited to synthesize vaccine and monoclonal antibody (mAb) against the surface glycoprotein of the COVID–19, as previous knowledge on SARS-CoV sGP (9, 14) would help in achieving the understanding and steps needed to mass production of a vaccine and mAb to target COVID–19. That being said, the efficient use of the bioinformatic computational tools in molecular biology like computer-assisted generation prediction of microbial epitope prediction, antigenic sequence generation from genomic data and homology modelling are few examples (11, 12, 13, 14) that had helped in targeting SARS-CoV and are in mass use to enable us to fight the current COVID–19 outbreak. The reports of the genome sequencing (11), studying the mutations evolving (4), prediction of proteins encoded (11, 14), drawing the phylogenetic tree of COVID–19 (4, 14) are few examples of how the scientific community has started its battle against the COVID–19. As the outbreak continues and has worsened in recent weeks (1, 8), for humanity it’s a race against time with COVID–19 to generate a vaccine, mAbs and an anti-viral drug that proves to be efficacious in the patients infected with COVID–19. Here, first, we compare the protein sequences of sGP of both SARS-CoV and COVID–19 to spot the similarities and contrast between the glycoproteins. Secondly, based on a decade long research finding on SARS-CoV sGP (4, 9, 17), the segments within the sGP of COVID–19 were planned to be tested in silico for their epitope attributes which can help generate a vaccine for COVID–19. Using segments of sGP with maximal similarities and contrast with SARS-CoV, prediction of monoclonal antibodies (mAbs) against the unique segments was attempted. The findings of antigenic components in COVID–19 sGP is expected to lay down the basis of further research on the segments discovered and in vitro testing in COVID–19 in labs and animal models to validate their utility. If proven to be effective in a small-scale animal trial, the vaccine generation and mAbs can prove useful in our massive ongoing research to combat COVID–19.